Ultrasonographic Evaluation of Diabetic Neuropathy

Diabetic Peripheral Neuropathy: Correlation Between Ultrasound Findings and Clinical Features

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02308059

Enrollment

106

Registered

2014-12-04

Start date

2012-04-30

Completion date

2014-12-31

Last updated

2014-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Brief summary

The current study aimed to evaluate the cross-sectional area (CSA) of peripheral nerves in people with diabetic peripheral neuropathy using ultrasonography and correlate the CSA with clinical and demographic data.

Detailed description

Patients with diabetic peripheral neuropathy (n=53) and a matched healthy control group (n=53) underwent blinded ultrasonography imaging of the sciatic, tibial and median nerves. Matching was performed according to patient body mass index (BMI), sex and age. CSAs of the nerves were recorded, and the associations between pain intensity (measured with a visual analog scale \[VAS\]), the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale, diabetes mellitus duration, BMI, HbA1c and blood glucose levels were evaluated.

Interventions

OTHERUltrasonographic evaluation of nerves in diabetic patients

Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy

OTHERUltrasonographic evaluation of nerves of healthy volunteers

evaluation of peripheral nerves and correlated with group I

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* type 2 diabetes mellitus * Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scores ≥ 12 * probable diabetic peripheral neuropathy according to the diabetic peripheral neuropathy criteria.

Exclusion criteria

* type 1 diabetes mellitus * hypothyroidism * LANSS pain scale scores \< 12 * body mass index (BMI) \> 35 * current pregnancy * histories of hereditary neuropathy, inflammatory neuropathy, nerve trauma, or other known causes of polyneuropathy; and the use of anti-neuropathic drugs.

Design outcomes

Primary

Measure	Time frame
Pain scores on the visual analog scale	3 years

Secondary

Measure	Time frame
Neuropathic pain scores on the Leeds Assessment of Neuropathic Symptoms and Signs pain scale	3 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026